Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. British journal of haematology Wierda, W. G., Byrd, J. C., O'Brien, S., Coutre, S., Barr, P. M., Furman, R. R., Kipps, T. J., Burger, J. A., Stevens, D. A., Sharman, J., Ghia, P., Flinn, I. W., Zhou, C., Ninomoto, J., James, D. F., Tam, C. S. 2019

View details for PubMedID 30740654